Issues Related to the Design and Interpretation of Clinical Trials of Salvage Therapy for Invasive Mold Infection
Open Access
- 1 December 2006
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 43 (11) , 1449-1455
- https://doi.org/10.1086/508455
Abstract
Invasive mold infection is a major cause of morbidity and mortality among severely immunocompromised individuals. We discuss the challenges involved in the design and interpretation of salvage antifungal trials, focusing on mold infection. We suggest that patients with refractory fungal infection be analyzed separately from those with intolerance to standard regimens because of the poorer prognosis of the former group. We propose a composite outcome assessment in which refractory infection is defined as infection associated with the worsening of at least 2 of the following 3 types of criteria: clinical, radiologic, and mycologic. Confounding variables, including heterogeneity in host factors, initial antifungal therapy, and selection bias, are discussed. Although randomized studies would provide the most credible results, the lack of an adequate number of patients to meet prespecified stratification criteria for all confounding variables makes such studies impractical. Given that randomized studies are unrealistic, studies involving carefully selected, matched, contemporaneous control subjects are likely to be the most useful alternative.Keywords
This publication has 60 references indexed in Scilit:
- Salvage Therapy for AspergillosisClinical Infectious Diseases, 2005
- Discordant Rise in Galactomannan Antigenemia in a Patient with Resolving Aspergillosis, Renal Failure, and Ongoing HemodialysisJournal of Clinical Microbiology, 2005
- Zygomycosis in a Tertiary‐Care Cancer Center in the Era ofAspergillus‐Active Antifungal Therapy: A Case‐Control Observational Study of 27 Recent CasesThe Journal of Infectious Diseases, 2005
- Detection of Galactomannan Antigenemia in Patients Receiving Piperacillin-Tazobactam and Correlations between In Vitro, In Vivo, and Clinical Properties of the Drug-Antigen InteractionJournal of Clinical Microbiology, 2004
- Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosisEuropean Journal of Haematology, 2004
- Breakthrough Zygomycosis after Voriconazole Treatment in Recipients of Hematopoietic Stem-Cell TransplantsNew England Journal of Medicine, 2004
- Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignanciesCancer, 2003
- A Double‐Blind, Randomized, Controlled Trial of Amphotericin B Colloidal Dispersion versus Amphotericin B for Treatment of Invasive Aspergillosis in Immunocompromised PatientsClinical Infectious Diseases, 2002
- Efficacy and Safety of Voriconazole in the Treatment of Acute Invasive AspergillosisClinical Infectious Diseases, 2002
- Incidence and risk factors for invasive fungal infections in allogeneic BMT recipientsBone Marrow Transplantation, 1997